Denver Neurological Research, LLC | Denver, CO

Research site

(Unclaimed)

Location

950 East Harvard Avenue, Suite 510, Denver, Colorado, United States of America

Site insights

Top conditions

Top treatments

ABBV-951

AR1001

Semaglutide

LY3154207

ATH-1017

Donanemab

Carbidopa

Ozanimod

Levodopa

Semagludtide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 13 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting

Early Alzheimer´s Disease

Drug: Placebo (semaglutide)

Drug: Semaglutide

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting

Early Alzheimer's Disease

Drug: Placebo (semaglutide)

Drug: Semagludtide

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD)

This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a ran...

Active, not recruiting

Alzheimer Disease

Dementia of Alzheimer Type

Drug: Placebo

Drug: ATH-1017

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease (Polaris-AD)

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling

Alzheimer Disease

Drug: Placebo

Drug: AR1001

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot fr...

Active, not recruiting

Parkinson's Disease (PD)

Drug: ABBV-951